UB Paderborn / Katalog / Suche / in CDI

Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis

Journal of rheumatology, 2005-12, Vol.32 (12), p.2405

2005

Link zum Volltext

Verfügbarkeit prüfen

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment

Journal of bone and mineral research, 2019-06, Vol.34 (6), p.1033-1040

2019

Link zum Volltext

Verfügbarkeit prüfen

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

The lancet. Diabetes & endocrinology, 2018-06, Vol.6 (6), p.445-454

2018

Link zum Volltext

Verfügbarkeit prüfen

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Journal of bone and mineral research, 2013-04, Vol.28 (4), p.746-752

2013

Link zum Volltext

Verfügbarkeit prüfen

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

Osteoporosis international, 2015-12, Vol.26 (12), p.2763-2771

2015

Link zum Volltext

Verfügbarkeit prüfen

Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis

Journal of bone and mineral research, 2005-06, Vol.20 (6), p.962-970

2005

Link zum Volltext

Verfügbarkeit prüfen

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover

Bone (New York, N.Y.), 2006-08, Vol.39 (2), p.237-243

2006

Link zum Volltext

Verfügbarkeit prüfen

FRI0289 Denosumab Treatment in Postmenopausal Women with Osteoporosis for Up to 9 Years: Results Through Year 6 of the Freedom Extension

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.529-530

2015

Link zum Volltext

Verfügbarkeit prüfen

SAT0463 Effect of Eight Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Five-Year Results from the Freedom Extension

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.761-761

2014

Link zum Volltext

Verfügbarkeit prüfen

SAT0342 Treatment of postmenopausal women with osteoporosis for six years with denosumab: Three-year results from the freedom extension

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.588-588

2013

Link zum Volltext

Verfügbarkeit prüfen

DISCONTINUATION OF DENOSUMAB AND ASSOCIATED VERTEBRAL FRACTURE INCIDENCE: ANALYSIS FROM FREEDOM AND ITS EXTENSION

OSTEOPOROSIS INTERNATIONAL, 2017, Vol.28, p.S53

2017

Link zum Volltext

Verfügbarkeit prüfen

Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension

ARTHRITIS & RHEUMATOLOGY, 2016, Vol.68

2016

Link zum Volltext

Verfügbarkeit prüfen

Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study

Osteoporosis international, 2006, Vol.17 (1), p.85-90

2006

Link zum Volltext

Verfügbarkeit prüfen

Incidence Rate of Potential Osteonecrosis of the Jaw Among Women with Postmenopausal Osteoporosis Treated with Prolia or Bisphosphonates

ARTHRITIS & RHEUMATOLOGY, 2015, Vol.67

2015

Link zum Volltext

Verfügbarkeit prüfen

FURTHER REDUCTION IN NONVERTEBRAL FRACTURE RATE IS OBSERVED FOLLOWING 3 YEARS OF DENOSUMAB TREATMENT: RESULTS WITH UP TO 7 YEARS IN THE FREEDOM EXTENSION

OSTEOPOROSIS INTERNATIONAL, 2014, Vol.25, p.S128

2014

Link zum Volltext

Verfügbarkeit prüfen

Further Reduction in the Nonvertebral Fracture Rate Is Observed Following 3 Years of Denosumab Treatment: Results With Up to 7 Years in the FREEDOM Extension

JOURNAL OF BONE AND MINERAL RESEARCH, 2013, Vol.28

2013

Link zum Volltext

Verfügbarkeit prüfen

DENOSUMAB (DMAB) TREATMENT FOR 6 YEARS MAINTAINS LOW FRACTURE INCIDENCE IN WOMEN >= 75 YEARS WITH POSTMENOPAUSAL OSTEOPOROSIS (PMO)

OSTEOPOROSIS INTERNATIONAL, 2013, Vol.24, p.S45

2013

Link zum Volltext

Verfügbarkeit prüfen

Low incidence of fracture maintained with long-term denosumab treatment in women aged >= 75 years with postmenopausal osteoporosis

AUSTRALASIAN JOURNAL ON AGEING, 2013, Vol.32, p.23

2013

Link zum Volltext

Verfügbarkeit prüfen

Identifying fracture risk in postmenopausal women

JAMA : the journal of the American Medical Association, 2002-03, Vol.287 (9), p.1109; author reply 1110

2002

Link zum Volltext

Verfügbarkeit prüfen

Further Reduction In Nonvertebral Fracture Rate Is Observed Following 3 Years Of Denosumab Treatment: Results With Up To 7 Years In The Freedom Extension

ARTHRITIS AND RHEUMATISM, 2013, Vol.65, p.S369

2013

Link zum Volltext

Verfügbarkeit prüfen

The Analysis of Denosumab Discontinuation and Associated Fracture Incidence in the FREEDOM Trial

ARTHRITIS AND RHEUMATISM, 2011, Vol.63 (10), p.S428

2011

Link zum Volltext

Verfügbarkeit prüfen

Low Fracture Incidence Is Maintained in Postmenopausal Women >= 75 Years with Osteoporosis with Long-Term Denosumab Treatment

ARTHRITIS AND RHEUMATISM, 2012, Vol.64 (10), p.S830

2012

Link zum Volltext

Verfügbarkeit prüfen

Further reduction in nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension

2014

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover

FRI0289 Denosumab Treatment in Postmenopausal Women with Osteoporosis for Up to 9 Years: Results Through Year 6 of the Freedom Extension

SAT0463 Effect of Eight Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Five-Year Results from the Freedom Extension

SAT0342 Treatment of postmenopausal women with osteoporosis for six years with denosumab: Three-year results from the freedom extension

DISCONTINUATION OF DENOSUMAB AND ASSOCIATED VERTEBRAL FRACTURE INCIDENCE: ANALYSIS FROM FREEDOM AND ITS EXTENSION

Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension

Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study

Incidence Rate of Potential Osteonecrosis of the Jaw Among Women with Postmenopausal Osteoporosis Treated with Prolia or Bisphosphonates

FURTHER REDUCTION IN NONVERTEBRAL FRACTURE RATE IS OBSERVED FOLLOWING 3 YEARS OF DENOSUMAB TREATMENT: RESULTS WITH UP TO 7 YEARS IN THE FREEDOM EXTENSION

Further Reduction in the Nonvertebral Fracture Rate Is Observed Following 3 Years of Denosumab Treatment: Results With Up to 7 Years in the FREEDOM Extension

DENOSUMAB (DMAB) TREATMENT FOR 6 YEARS MAINTAINS LOW FRACTURE INCIDENCE IN WOMEN >= 75 YEARS WITH POSTMENOPAUSAL OSTEOPOROSIS (PMO)

Low incidence of fracture maintained with long-term denosumab treatment in women aged >= 75 years with postmenopausal osteoporosis

Identifying fracture risk in postmenopausal women

Further Reduction In Nonvertebral Fracture Rate Is Observed Following 3 Years Of Denosumab Treatment: Results With Up To 7 Years In The Freedom Extension

The Analysis of Denosumab Discontinuation and Associated Fracture Incidence in the FREEDOM Trial

Low Fracture Incidence Is Maintained in Postmenopausal Women >= 75 Years with Osteoporosis with Long-Term Denosumab Treatment

Further reduction in nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension

Percentage of women achieving non-osteoporotic BMD T-scores at the lumbar spine (LS) and total hip (TH) during up to 8 years of Denosumab (Dmab) treatment

Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension

Suchergebnisse filtern